The race for an Ebola therapy begins

The New York Times (US)Independent🔒CenterFactual 85Objective 755 days ago

The CIA and the Office of the Director of National Intelligence attempted to dismiss 19 intelligence officers early in the second Trump administration. The action was reportedly related to their work on diversity initiatives. The court has intervened, blocking these firings.

Bias read (Center): The article presents a factual account of the attempt to fire intelligence officers and the subsequent court intervention. There is no clear ideological framing or emphasis on specific political perspectives. The focus remains on the legal and administrative actions taken by the agencies involved.

Why these scores (Factual 85 · Objective 75): Factuality is high as the claim aligns with the cross-source consensus that the CIA and ODNI attempted to fire 19 officers under the Trump administration. Objectivity is lower due to the article's focus on the political implications and potential consequences of the firings, suggesting a somewhat bi

STAT NewsIndependentCenteryesterday

The article discusses several topics, including legislative efforts to increase diversity in clinical trials, a new clinical trial for an Ebola therapy in the Democratic Republic of the Congo, and a sports-related study on male marathon runners. Regarding clinical trials, Republican lawmakers are pushing for greater diversity after the Trump administration reduced focus on diversity, equity, and inclusion (DEI). The FDA had planned to implement a 2022 law requiring drug companies to submit plans for diverse clinical trials, but the Trump administration removed this guidance. Meanwhile, a WHO-led trial is testing two potential therapies—remdesivir and MBP-134—for treating the Bundibugyo strain of Ebola. The DRC has reported 1,406 Ebola cases with 438 deaths. Separately, a study published in Nature found that male marathon runners are more prone to 'hitting the wall' due to physiological differences, though the exact reasons remain unclear.

Bias read (Center): The article presents a balanced view of the legislative efforts regarding clinical trial diversity, noting both the actions of Republican lawmakers and the impact of previous administrations. While it highlights the controversy around DEI policies, it does not overtly favor one side. The coverage of

STAT NewsIndependentCenter2 days ago

The article discusses how Republican lawmakers are pushing the Trump administration's Food and Drug Administration (FDA) to prioritize diversity in clinical trials. It notes that the Trump administration initially targeted diversity, equity, and inclusion (DEI) initiatives, removing references to DEI from HHS agency websites. However, advocates argue that ensuring diverse participant enrollment in clinical trials is crucial for making sure treatments are effective across different populations. The piece highlights the tension between the administration's broader DEI policies and the specific need for demographic representation in medical research.

Bias read (Center): The article presents both perspectives: the administration's stance on DEI and the counterargument from clinical trial advocates. While it frames the issue within the context of political action (GOP lawmakers pushing the FDA), it does not overtly favor one side over the other. The language remains